Greencross Chemists Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 15-12-2024
- Paid Up Capital ₹ 7.40 M
as on 15-12-2024
- Company Age 14 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 37.21%
(FY 2022)
- Profit 96.43%
(FY 2022)
- Ebitda -30.62%
(FY 2022)
- Net Worth 20.52%
(FY 2022)
- Total Assets -3.04%
(FY 2022)
About Greencross Chemists Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 7.40 M, as per Ministry of Corporate Affairs (MCA) records.
Johny Antony, Poothokkaran Wilson, Varghese Anthappan, and Nine other members serve as directors at the Company.
- CIN/LLPIN
U24233KL2010PTC026594
- Company No.
026594
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Aug 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Thrissur, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Greencross Chemists Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deljo Muttath  | Managing Director | 07-Feb-2020 | Current |
Board Members(11)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Johny Antony | Director | 26-Jun-2014 | Current |
| Poothokkaran Wilson | Director | 26-Jun-2014 | Current |
| Varghese Anthappan | Director | 24-Aug-2010 | Current |
| Chirayath Paul | Director | 26-Jun-2014 | Current |
| Pulikken Sebi | Director | 07-Feb-2020 | Current |
| Plavinkuttathil Balakrishnan | Director | 07-Feb-2020 | Current |
Financial Performance of Greencross Chemists Pharma.
Greencross Chemists Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 37.21% increase. The company also saw a substantial improvement in profitability, with a 96.43% increase in profit. The company's net worth Soared by an impressive increase of 20.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Greencross Chemists Pharma?
In 2021, Greencross Chemists Pharma had a promoter holding of 29.73% and a public holding of 70.27%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Bhagyaratna Kuries (India) Private LimitedActive 15 years 8 months
Poothokkaran Wilson is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Greencross Chemists Pharma?
Unlock and access historical data on people associated with Greencross Chemists Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Greencross Chemists Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Greencross Chemists Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
